IL-6 signaling may engage the Akt/mTOR and SHP2/STAT3 pathway to modulate HSPC maintenance. Besides, it is a particularly important modulator in mediating rapid myeloid cell recovery during chemotherapy-induced neutropenia. The gene discussed is AKT1; the disease is neutropenia.